These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30312106)

  • 1. Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension.
    Nikolic I; Yung LM; Yang P; Malhotra R; Paskin-Flerlage SD; Dinter T; Bocobo GA; Tumelty KE; Faugno AJ; Troncone L; McNeil ME; Huang X; Coser KR; Lai CSC; Upton PD; Goumans MJ; Zamanian RT; Elliott CG; Lee A; Zheng W; Berasi SP; Huard C; Morrell NW; Chung RT; Channick RW; Roberts KE; Yu PB
    Am J Respir Crit Care Med; 2019 Apr; 199(7):891-902. PubMed ID: 30312106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced circulating BMP10 and BMP9 and elevated endoglin are associated with disease severity, decompensation and pulmonary vascular syndromes in patients with cirrhosis.
    Owen NE; Alexander GJ; Sen S; Bunclark K; Polwarth G; Pepke-Zaba J; Davenport AP; Morrell NW; Upton PD
    EBioMedicine; 2020 Jun; 56():102794. PubMed ID: 32454407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of
    Hodgson J; Swietlik EM; Salmon RM; Hadinnapola C; Nikolic I; Wharton J; Guo J; Liley J; Haimel M; Bleda M; Southgate L; Machado RD; Martin JM; Treacy CM; Yates K; Daugherty LC; Shamardina O; Whitehorn D; Holden S; Bogaard HJ; Church C; Coghlan G; Condliffe R; Corris PA; Danesino C; Eyries M; Gall H; Ghio S; Ghofrani HA; Gibbs JSR; Girerd B; Houweling AC; Howard L; Humbert M; Kiely DG; Kovacs G; Lawrie A; MacKenzie Ross RV; Moledina S; Montani D; Olschewski A; Olschewski H; Ouwehand WH; Peacock AJ; Pepke-Zaba J; Prokopenko I; Rhodes CJ; Scelsi L; Seeger W; Soubrier F; Suntharalingam J; Toshner MR; Trembath RC; Vonk Noordegraaf A; Wort SJ; Wilkins MR; Yu PB; Li W; Gräf S; Upton PD; Morrell NW
    Am J Respir Crit Care Med; 2020 Mar; 201(5):575-585. PubMed ID: 31661308
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulation of the ALK1 ligands, BMP9 and BMP10.
    Li W; Salmon RM; Jiang H; Morrell NW
    Biochem Soc Trans; 2016 Aug; 44(4):1135-41. PubMed ID: 27528761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan.
    Takahashi Y; Yamamoto K; Sakao S; Takeuchi T; Suda R; Tanabe N; Tatsumi K
    BMC Pulm Med; 2021 Mar; 21(1):89. PubMed ID: 33726742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells.
    Upton PD; Davies RJ; Trembath RC; Morrell NW
    J Biol Chem; 2009 Jun; 284(23):15794-804. PubMed ID: 19366699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exacerbated inflammatory signaling underlies aberrant response to BMP9 in pulmonary arterial hypertension lung endothelial cells.
    Szulcek R; Sanchez-Duffhues G; Rol N; Pan X; Tsonaka R; Dickhoff C; Yung LM; Manz XD; Kurakula K; Kiełbasa SM; Mei H; Timens W; Yu PB; Bogaard HJ; Goumans MJ
    Angiogenesis; 2020 Nov; 23(4):699-714. PubMed ID: 32813135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What's new in the treatment of portopulmonary hypertension?
    DuBrock HM; Channick RN; Krowka MJ
    Expert Rev Gastroenterol Hepatol; 2015 Jul; 9(7):983-92. PubMed ID: 25882070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension.
    Tu L; Desroches-Castan A; Mallet C; Guyon L; Cumont A; Phan C; Robert F; Thuillet R; Bordenave J; Sekine A; Huertas A; Ritvos O; Savale L; Feige JJ; Humbert M; Bailly S; Guignabert C
    Circ Res; 2019 Mar; 124(6):846-855. PubMed ID: 30636542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portopulmonary Hypertension: Management and Liver Transplantation Evaluation.
    DuBrock HM
    Chest; 2023 Jul; 164(1):206-214. PubMed ID: 36649754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other causes of PAH (schistosomiasis, porto-pulmonary hypertension and hemolysis-associated pulmonary hypertension).
    Souza R; Fernandes CJ; Jardim CV
    Semin Respir Crit Care Med; 2009 Aug; 30(4):448-57. PubMed ID: 19634084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Portopulmonary hypertension.
    Krowka MJ
    Semin Respir Crit Care Med; 2012 Feb; 33(1):17-25. PubMed ID: 22447257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric pulmonary arterial hypertension due to a novel homozygous GDF2 missense variant affecting BMP9 processing and activity.
    Chomette L; Hupkens E; Romitti M; Dewachter L; Vachiéry JL; Bailly S; Costagliola S; Smits G; Tillet E; Bondue A
    Am J Med Genet A; 2023 Aug; 191(8):2064-2073. PubMed ID: 37249087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BMP9/10 in Pulmonary Vascular Complications of Liver Disease.
    Rochon ER; Krowka MJ; Bartolome S; Heresi GA; Bull T; Roberts K; Hemnes A; Forde KA; Krok KL; Patel M; Lin G; McNeil M; Al-Naamani N; Roman BL; Yu PB; Fallon MB; Gladwin MT; Kawut SM
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1575-1578. PubMed ID: 32083953
    [No Abstract]   [Full Text] [Related]  

  • 15. Portopulmonary hypertension in the current era of pulmonary hypertension management.
    Savale L; Guimas M; Ebstein N; Fertin M; Jevnikar M; Renard S; Horeau-Langlard D; Tromeur C; Chabanne C; Prevot G; Chaouat A; Moceri P; Artaud-Macari É; Degano B; Tresorier R; Boissin C; Bouvaist H; Simon AC; Riou M; Favrolt N; Palat S; Bourlier D; Magro P; Cottin V; Bergot E; Lamblin N; Jaïs X; Coilly A; Durand F; Francoz C; Conti F; Hervé P; Simonneau G; Montani D; Duclos-Vallée JC; Samuel D; Humbert M; De Groote P; Sitbon O
    J Hepatol; 2020 Jul; 73(1):130-139. PubMed ID: 32145258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Portopulmonary hypertension.
    Lv Y; Han G; Fan D
    Scand J Gastroenterol; 2016 Jul; 51(7):795-806. PubMed ID: 27002212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Portopulmonary hypertension: prognosis and management in the current treatment era - results from the REHAP registry.
    Lazaro Salvador M; Quezada Loaiza CA; Rodríguez Padial L; Barberá JA; López-Meseguer M; López-Reyes R; Sala-Llinas E; Alcolea S; Blanco I; Escribano-Subías P;
    Intern Med J; 2021 Mar; 51(3):355-365. PubMed ID: 31943676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current management approaches to portopulmonary hypertension.
    Savale L; O'Callaghan DS; Magnier R; Le Pavec J; Hervé P; Jaïs X; Seferian A; Humbert M; Simonneau G; Sitbon O
    Int J Clin Pract Suppl; 2011 Jan; (169):11-8. PubMed ID: 21176011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Portopulmonary hypertension: a report from the US-based REVEAL Registry.
    Krowka MJ; Miller DP; Barst RJ; Taichman D; Dweik RA; Badesch DB; McGoon MD
    Chest; 2012 Apr; 141(4):906-915. PubMed ID: 21778257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Portopulmonary Hypertension in Liver Disease Presenting in Childhood.
    Ecochard-Dugelay E; Lambert V; Schleich JM; Duché M; Jacquemin E; Bernard O
    J Pediatr Gastroenterol Nutr; 2015 Sep; 61(3):346-54. PubMed ID: 25885880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.